NCT02389738 - Brain Interstitium Temozolomide Concentration Pre and Post Regadenoson Administration | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 28, 2015

Primary Completion Date

February 29, 2016

Study Completion Date

February 1, 2018

Conditions

Blood Brain Barrier Defect

Interventions

DRUG

Regadenoson

Regadenoson administration on post-op day 2 after temozolomide administration. Temozolomide plasma and dialysate concentrations will be obtained over 18 hours post temozolomde administration.

DRUG

Temozolomide

Temozolomide administration on post-op day 1 and 2. Temozolomide plasma and dialysate concentrations will be obtained over 18 hours post temozolomde administration.

DEVICE

Microdialysis catheter

Microdialysis catheter placement post surgical resection and removed at the bedside after completion of obtaining all dialysate collections.

Trial Locations (1)

21287

Johns Hopkins Hospital, Baltimore

All Listed Sponsors

lead

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

OTHER